SCHEMBL18151703

SCHEMBL18151703

O=C(Cc1cccc(S(=O)(=O)NC2CC2)c1)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.43
ALDH1A1 P00352 1/20 0.43
RORC P51449 7/20 0.42
MAPT P10636 6/20 0.42
CYP2D6 P10635 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
IDH2 P48735 2/20 0.41
POLB P06746 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
TP53 P04637 5/20 0.40
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18156924 0.91 LMNA (0.43) LMNAALDH1A1RORCMAPTCYP2D6
SCHEMBL18151843 0.90 MEN1 (0.43) LMNAALDH1A1RORCMAPTCYP2D6
SCHEMBL18151474 0.90 LMNA (0.44) LMNAALDH1A1RORCMAPTCYP2D6
SCHEMBL18151627 0.90 RORC (0.48) RORCMAPTCYP2D6KMT2AMEN1
SCHEMBL18151519 0.87 RORC (0.54) LMNAALDH1A1RORCMAPTCYP2D6
SCHEMBL18156923 0.84 LMNA (0.43) LMNAALDH1A1RORCMAPTCYP2D6
SCHEMBL18156949 0.84 PDK1 (0.46) LMNAALDH1A1RORCMAPTKMT2A
SCHEMBL18151831 0.83 RORC (0.53) LMNARORCMAPTCYP2D6KMT2A
SCHEMBL18151612 0.81 RORC (0.44) LMNAALDH1A1RORCMAPTCYP2D6
SCHEMBL18156907 0.81 RORC (0.47) LMNAALDH1A1RORCMAPTCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077372-B1 ROR GAMMA (RORY) MODULATORS LEAD PHARMA HOLDING BV (NL) 2019-02-06 EP claimed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US claimed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US claimed
EP-3077372-B1 ROR GAMMA (RORY) MODULATORS LEAD PHARMA HOLDING BV (NL) 2019-02-06 EP disclosed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US disclosed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US disclosed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US disclosed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS RORC, RORA, RORB LMNA 3089/4885ALDH1A1 1054/4885RORC 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.